1-(4,6-Dimethylpyrimidin-2-yl)piperidin-4-amine → 4-(3-(1-(4,6-Dimethylpyrimidin-2-yl)piperidin-4-ylamino)-2-hydroxypropoxy)phenol

HRID 221643노트

반응식

HRID 221643 반응식
C([Si](C)(C)[O:6][C:7]1[CH:12]=[CH:11][C:10]([O:13][CH2:14][CH:15]2[CH2:17][O:16]2)=[CH:9][CH:8]=1)(C)(C)C.[CH3:20][C:21]1[CH:26]=[C:25]([CH3:27])[N:24]=[C:23]([N:28]2[CH2:33][CH2:32][CH:31]([NH2:34])[CH2:30][CH2:29]2)[N:22]=1>CC(O)C.CS(C)=O>[CH3:20][C:21]1[CH:26]=[C:25]([CH3:27])[N:24]=[C:23]([N:28]2[CH2:29][CH2:30][CH:31]([NH:34][CH2:17][CH:15]([OH:16])[CH2:14][O:13][C:10]3[CH:9]=[CH:8][C:7]([OH:6])=[CH:12][CH:11]=3)[CH2:32][CH2:33]2)[N:22]=1

참가 물질

4

반응물 2

HCID 47782891-(4,6-Dimethylpyrimidin-2-yl)piperidin-4-amineHCID 19385012Tert-butyldimethyl(4-(oxiran-2-ylmethoxy)phenoxy)silane

생성물 1

HCID 249371384-(3-(1-(4,6-Dimethylpyrimidin-2-yl)piperidin-4-ylamino)-2-hydroxypropoxy)phenol수율 64%

시약·촉매·용매 1

HCID 87082799iPrOH DMSO용매

실험 절차

Synthesis followed SP6 (iPrOH:DMSO 1:1, 120° C., 35 h), using 200 μmol tert-butyldimethyl(4-(oxiran-2-ylmethoxy)phenoxy)silane and 1-(4,6-dimethylpyrimidin-2-yl)piperidin-4-amine to give O-silylated intermediate upon purification by prep. HPLC (reversed phase) and prep. TLC (1 mm silica gel, PE/CH2Cl2/MeOH 6:4:1) with 64% yield. Product was obtained by deprotection according to SP7 and purification by prep. HPLC (reversed phase) and prep. TLC (1 mm silica gel, PE/CH2Cl2/MeOH 3:7:1.5) with 10% yield.

후처리

  1. customSynthesis
  2. customto give O-silylated intermediate
  3. customupon purification by prep
  4. customProduct was obtained by deprotection
  5. customaccording to SP7 and purification by prep

출처 및 근거

ORD 기록
ord-ba404fe68ad4460383aef063fa45f07b
출처 데이터셋
uspto-grants-2012_06
특허 번호
US08207174B2

반응 노트

불러오는 중…